Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
SAGE.US
id: 40
On June 15, 2021, an Analyst of financial company Truist Joon Lee published a negative investment note about SAGE clinical results.
On this news, SAGE shares dropped more than 19% and lost $835 million of its capitalization.
Taking into account the publicly available facts and analytics, there is reason to suspect that the analyst's work was at least unprofessional and negligent, and possibly the intention of price manipulation.
Case Status
Attorney Investigation
Alleged Offence
Misleading Statements
Price manipulation
Insider Trading
Malpractice
Negligence
Omissions
Suspected Party
Influencer
Investment Bank
Security Type
Stocks
Trade Direction
Long
Shock Event Date
15 June 2021
Collecting participants…

Sage Therapeutic

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum de...

    Ticker
    SAGE.US
    ISIN
    US78667J1088
    CIK
    1597553
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    215 First Street, Cambridge, MA, United States, 02142